• Advanced Medical Optics (Santa Ana, California) reported FDA clearance for the iFS advanced femtosecond laser. The laser's inverted bevel-in side cut angle is designed to provide an easy flap lift, increase post-operative flap adhesion and enhance the biomechanical stability of the post-LASIK cornea. With full customization capabilities, it also produces an elliptical flap to enhance surgical options and includes IntraLase-Enabled Keratoplasty (IEK). Advanced Medical Optics makes ophthalmic surgical devices and eye care products.

• Biopure (Cambridge, Massachusetts) said results from its Phase II coronary revascularization trial have been published in EuroIntervention Journal. The COR-0002 trial is a single-blind, open-label, single-center, crossover pilot study where subjects underwent coronary balloon occlusion, with and without oxygenated HBOC-201. The primary objective of the study was to test the hypothesis that intracoronary infusion of HBOC-201 during brief, total coronary artery occlusion would preserve left ventricular function. The primary endpoints in COR-0002 were left ventricular diastolic relaxation indices as assessed by left ventricular pressure-volume loops and ST segment changes as assessed via electrocardiograms. The study concluded that HBOC-201 was indeed capable of preserving left ventricular function, likely through maintenance of myocardial oxygenation. Biopure makes oxygen therapeutics.

• LifeWatch (Buffalo Grove, Illinois) said it has launched an atrial fibrillation (AF) patient care program for monitoring patients across the nation. The company said it has expanded its customized patient care program for the "untapped" market of periop monitoring of those patients undergoing AF catheter and surgical ablation procedures. The LifeWatch AF patient care program represents the first disease state management program to be supported by the ACT service platform. The company has partnered with cardiac institutions to identify additional patient care programs in CHF and pediatrics. These programs are expected to expand ACT use and allow LifeWatch to provide a telehealth model of care that focuses on specific physician and patient needs with the goals of improving patient care and outcomes. LifeWatch is a provider of ambulatory cardiac monitoring services.